What is Zacks Research’s Estimate for TMO Q2 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities researchers at Zacks Research lowered their Q2 2025 EPS estimates for Thermo Fisher Scientific in a report issued on Monday, May 19th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $5.19 per share for the quarter, down from their prior estimate of $5.22. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q3 2025 earnings at $5.52 EPS, Q4 2025 earnings at $6.40 EPS, FY2025 earnings at $22.26 EPS, Q1 2026 earnings at $5.61 EPS, Q3 2026 earnings at $5.70 EPS, Q4 2026 earnings at $6.10 EPS, FY2026 earnings at $24.34 EPS and Q1 2027 earnings at $6.95 EPS.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the company earned $5.11 earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year.

Several other brokerages also recently issued reports on TMO. Raymond James reiterated an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. UBS Group reduced their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Royal Bank of Canada reduced their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, Argus dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $607.43.

Thermo Fisher Scientific Trading Down 3.8%

NYSE:TMO opened at $397.89 on Wednesday. Thermo Fisher Scientific has a one year low of $390.50 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company’s 50-day simple moving average is $447.48 and its 200 day simple moving average is $507.46. The firm has a market capitalization of $150.20 billion, a P/E ratio of 24.07, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,075 shares of company stock valued at $7,305,942. Company insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $25,000. Barrett & Company Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. Missouri Trust & Investment Co acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Finally, Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.